Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CytoMegaloVirus Alternate Donor Study of Pre-Emptive Cellular Therapy
ISRCTN75391842Phase 2Completed
- Sponsor
- Kuur Therapeutics
- Start
- Jun 2009
- Modality
- Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, randomised, open-label trial of adimlecleucel in cytomegalovirus disease (CMV) (2 arms), sponsored by Kuur Therapeutics. Primary endpoint: Peak circulating CMV-reactive T-cell response. Started Jun 2009; status: completed.
02
Drugs
adimlecleucel
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ISRCTN75391842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN75391842.